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BACKGROUND: Growth factor receptors such as epidermal growth factor receptor 1 and human epidermal growth re-
ceptor 2 (HER2) are overexpressed in certain cancer cells. Antibodies against these receptors (eg. cetuximab and
transtuzumab [Herceptin]) have shown therapeutic value in cancer treatment. The existing methods for the quantifi-
cation of these receptors in tumors involve immunohistochemistry or DNA quantification, both in extracted tissue
samples. The goal of the study was to evaluate whether an optical fiber-based technique can be used to quantify the
expression of multiple growth factor receptors simultaneously. METHODS: The authors examined HER2 expression
using the monoclonal antibody trastuzumab as a targeting ligand to test their system. They conjugated trastuzumab
to 2 different Alexa Fluor dyes with different excitation and emission wavelengths. Two of the dye conjugates were
subsequently injected intravenously into mice bearing HER2-expressing subcutaneous tumors. An optical fiber was
then inserted into the tumor through a 30-gauge needle, and using a single laser beam as the excitation source, the
fluorescence emitted by the 2 conjugates was identified and quantified by 2-photon optical fiber fluorescence.
RESULTS: The 2 conjugates bound to the HER2-expressing tumor competitively in a receptor-specific fashion, but
they failed to bind to a similar cell tumor that did not express HER2. The concentration of the conjugate present in
the tumor as determined by 2-photon optical fiber fluorescence was shown to serve as an index of the HER2 expres-
sion levels. CONCLUSIONS: These studies offer a minimally invasive technique for the quantification of tumor recep-
tors simultaneously. Cancer 2012;118:2148-56. VC 2011 American Cancer Society.
KEYWORDS: double-clad optical fiber, 2-photon excitation, cancer targeting, growth factor receptor quantification,
HER2, Herceptin.
INTRODUCTION
The overexpression of growth factor receptors has been implicated in the growth and metastasis of multiple human
neoplasms.1 Cell surface receptors, such as the ErbB family proteins epidermal growth factor receptor (EGFR), human
epidermal growth receptor 2 (HER2), HER3, and HER4,2-5 vascular endothelial growth factor receptor (VEGFR),2,6
platelet-derived growth factor receptor,7-10 fibroblast growth factor receptor,11-14 and insulinlike growth factor 1 receptor
(IGFR),15,16 have been shown to be overexpressed in human cancers. Monoclonal antibodies produced against several of
these receptors, such as trastuzumab (Herceptin; anti-HER2), cetuximab (anti-EGFR), and bevacizumab (anti-VEGFR),
have either been shown to have therapeutic value in tumor suppression or are undergoing evaluation in clinical trials.2,17
Assessing the expression of these receptors on tumors is generally performed by conventional immunohistochemical
methods or by nucleic acid quantification and determination of the relevant gene copies, in both cases using isolated
tumor tissues. The development of a minimally invasive method for the in vivo quantification of these receptors would
have utility in determining the value of a targeted therapy directed against these receptors, as well as for the repeated
imaging and monitoring of antibody therapy against receptor-expressing tumor.
One of the most extensively investigated tumor-related growth factor receptors is HER2, a disease marker for breast
cancer. HER2 is overexpressed in approximately 25% of breast cancers.18-20 Trastuzumab, a US Food and Drug
DOI: 10.1002/cncr.26487, Received: May 10, 2011; Revised: July 11, 2011; Accepted: July 15, 2011, Published online August 25, 2011 in Wiley Online Library
(wileyonlinelibrary.com)
Corresponding author: Drs. Thommey P. Thomas, PhD, and James R. Baker, Jr, MD, Michigan Nanotechnology Institute for Medicine and Biological Sciences and
Department of Internal Medicine, University of Michigan, 9220 MSRB III, Box 0648, Ann Arbor, MI 48109; thommey@umich.edu and jbakerjr@umich.edu
1Michigan Nanotechnology Institute for Medicine and Biological Sciences, Ann Arbor, Michigan; 2Department of Internal Medicine, University of Michigan, Ann
Arbor, Michigan; 3Center for Ultrafast Optical Science, University of Michigan, Ann Arbor, Michigan; 4Department of Electrical Engineering, National Changhua
University of Education, Changhua, Taiwan; 5Department of Biomedical Engineering, University of Texas at San Antonio, San Antonio, Texas
The first 2 authors contributed equally to this article.
2148 Cancer April 15, 2012
Original Article
Administration (FDA)-approved humanized antibody
against HER2, is currently used for targeted therapy
against breast cancer.21-24 However, treatment with tras-
tuzumab is costly, can be associated with cardiotoxic-
ity,25,26 and is only effective against tumors with HER2
amplification.27-29 Therefore, accurate quantification of
HER2 expression in tumors before treatment with trastu-
zumab is crucial to the success of the therapy.
The most commonly used method to assess HER2
expression is in vitro immunohistochemical staining of
isolated tumor tissue samples using HER2 antibodies.30,31
The assessment is based on scoring the histochemical slides
as 0 (<10% of any degree of staining), 1þ (>10% incom-
plete staining), 2þ (>10% weak staining), or 3þ (>10%
intense staining),24 and only cases with 3þ staining are
considered for trastuzumab therapy.22,27-29 However,
there are several limitations in the immunohistochemical
assessment of HER2, and the results may not always pro-
vide accurate decision points for instituting trastuzumab
therapy.24,32-39 The specific scoring of the slides for mem-
brane staining is, at best, semiquantitative and generates
only relative numbers even when using computerized algo-
rithm-based grading. The uncertainty in these assessments
is evident from the recent amendment by the American
Society of Clinical Oncology/College of American Pathol-
ogists, where the criterion for the 3þ HER2 is tumors
showing ‘‘>30% intense staining,’’ although the FDA still
recommends a standard of ‘‘>10% intense staining.’’39-41
Equivocal samples (2þ) must be further analyzed by the
fluorescence in situ hybridization (FISH) test.40 Although
FISH may give more objective scoring criteria (>6 and
<4 copies of the gene as positive and negative, respec-
tively, and 5 copies of the gene as equivocal), it is an expen-
sive and time-consuming technique that requires a highly
skilled clinician and has technical challenges including fix-
ation problems, nonintact nuclei, and the inability to pre-
serve slides for further review.24,39,42-46 Importantly, both
the immunohistochemical and FISH methods have the
drawback of requiring tissue samples to be removed by
invasive surgical procedures. Needle aspiration using 20-
to 25-gauge needles can make it challenging to obtain suf-
ficient tissue to do the analyses.43,47,48 Moreover, the
results of the in vitro methods can be influenced by the
biochemical changes occurring during the recovery; the
overall result of this being that recent studies estimate
20% of the currently used HER2 quantification results
produce inaccurate results.39,41 Furthermore, these techni-
ques do not assess pathways identified for trastuzumab re-
sistance because of the coexpression and involvement of
other receptors, such as IGFR,49,50 suggesting the need for
identifying multiple tumor receptors to predict the utility
of trastuzumab therapy.
Our previous studies have shown that a 2-photon
optical fiber fluorescence-based detection system can
quantify tissue fluorescence both in vitro and in live ani-
mals.51-53 The broad range of wavelengths that can excite
the 2-photon excitation also allows fluorescently tagged
probes with different excitation/emission wavelengths to
be simultaneously quantified using a single laser beam.
Therefore, this method has the potential for the simulta-
neous quantification of multiple different receptors
expressed on a tumor.
The hypothesis of this study is that a 2-photon opti-
cal fiber fluorescence probe inserted into a tumor can
simultaneously quantify 2 different, fluorescently tagged
probes targeted to a tumor in vivo, which in turn can serve
as an index for the amount of receptors present in the
tumor. To test this hypothesis, we synthesized and tested
different fluorescently tagged trastuzumab conjugates.
Two of these conjugates were intravenously injected into
a mouse bearing HER2-expressing tumors, and their fluo-
rescence was quantified using the 2-photon optical fiber
fluorescence probe. We show the measurement of the 2
conjugates under receptor-saturating conditions, demon-
strating the feasibility of this approach for quantifying the
actual numbers of multiple receptors simultaneously.
MATERIALS AND METHODS
Materials
The carboxylic acid, succinimidyl esters of Alexa Fluor
594 (Excitation/Emission: 590/617; e ¼ 92,000 cm1
M1), Alexa Fluor 633 (Excitation/Emission: 632/647; e
¼ 100,000 cm1 M1), and Alexa Fluor 660 (Excitation/
Emission: 663/690; e ¼ 132,000 cm1 M1), was
obtained from Invitrogen (Carlsbad, Calif). Trastuzumab
was purchased from the University of Michigan Hospi-
tals. Spectra/Por dialysis membrane (MWCO 3500) and
Millipore Centricon ultrafiltration membrane (YM-10)
were obtained from Fisher Scientific (Pittsburgh, Pa).
MCA207-control and MCA207-HER2 cells were
obtained from Dr. Kevin Mc Donaugh at the University
of Kentucky.52 Female, severe combined immunodefi-
ciency (SCID) mice were purchased from Charles River
Laboratories (Wilmington, Mass). Dulbecco modified
Eagle medium (DMEM) cell culture medium, fetal calf
serum (FCS), trypsin-ethylenediaminetetraacetic acid,
penicillin/streptomycin, and Dulbecco phosphate-
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buffered saline (PBS; pH 7.4) were from Gibco/BRL
(Gaithersburg, Md). All other reagents were from Aldrich
(St Louis, Mo). The double-clad fiber used in this study
had an inner core diameter of 6 lm, with a numerical
aperture of 0.15. The diameter of the inner cladding was
123 lm, with a numerical aperture of 0.46 (P6/123DC;
Liekki Corporation, Lohja, Finland).
Methods
Synthesis and purification of trastuzumab-Alexa
Fluor conjugates
Our previous studies have shown the targeting of a
fluorescein isothiocyanate (FITC)-trastuzumab conjugate
into mouse tumors.52 As FITC is known to be highly pho-
tounstable, reliable quantitative information may not be
possible with FITC. To overcome this problem, in the
current study we synthesized Alexa Fluor conjugates with
known photostable properties. To a 5 mg/mL solution of
trastuzumab-PBS we slowly added the Alexa Fluor dyes in
dimethylsulfoxide (5 excess), mixing them well using a
magnetic stirrer. The reaction mixture was stirred contin-
uously overnight at room temperature, and the products
were subjected to column chromatography using a Sepha-
dex G25 column (1  30 cm) equilibrated with 10 mM
phosphate buffer pH 7.0, performed at 4C. One-millili-
ter fractions were collected, and the absorbance of the col-
lected fractions was determined at 280 nm as well as at the
absorbance maximum for each dye. In Figure 1A is given
a typical elution pattern for the separation of the free dye
from the conjugates, shown for the trastuzumab-Alexa
Fluor 633 conjugate, with similar conjugate and free dye
elution volumes obtained for the other conjugates synthe-
sized. Appropriate conjugate fractions were collected and
concentrated using a Centricon (Millipore, Bedford,
Mass; 10 K molecular weight cutoff) filter device. The
protein concentration of the sample was determined using
a bicinchoninic acid reagent (Pierce, Rockford, Ill), fol-
lowing the vendor’s protocol.
Two-photon optical fiber fluorescence
system instrumentation
We used a recently developed solid-core double-clad
optical fiber, having improved sensitivity for quantifica-
tion of low-level tissue fluorescence.53 The length of the
fiber used was approximately 1 m. Femtosecond laser
pulses (20 mW) generated from a Ti:sapphire oscillator
(Mira 900; Coherent, Santa Clara, Calif) with a pulse du-
ration of 150 fs and center wavelength of 800 nm were
used as the excitation source; the pulses were prechirped
using a grating pair to precompensate the dispersion of
the optical fiber, so the pulse duration at the excitation
point was also close to 150 fs. Double-clad fiber was
directly inserted into the dye solutions, cell pellets, and
the tumor through a 30-gauge needle. The fluorescence
signal was collected back through the same fiber and sent
through band pass filters before being detected using a
photon counting photomultiplier tube (PMT). The sig-
nals from the PMT were then analyzed by a computer to
generate the 2-photon optical fiber fluorescence photon
counts.
Figure 1. (A) Gel filtration purification of the trastuzumab-
Alexa Fluor 633 conjugate is shown. The conjugate was syn-
thesized as described in Methods, and 1 mL of the reaction
mixture was applied onto a 25-cm Sephadex G25 column equi-
librated with 10 mM phosphate buffer, pH 7.0. One-milliliter
fractions were collected, and the absorbance of the fractions
was determined at 280 nm (solid line) and at 632 nm (dashed
line). In this typical experiment, fractions 6 to 10 (trastuzumab-
Alexa Fluor 633) were pooled, concentrated, and used for bio-
logical studies. The peak eluted at fractions 30 to 60 represent
the free dye, and that which eluted between fractions 12 to 20
may represent free trastuzumab. (B) Flow cytometric analysis
of the cellular binding of trastuzumab-Alexa Fluor 633 is
shown. The indicated cells were plated in 24-wells and incu-
bated with different concentrations of the conjugate for 1 hour
at 37C. The cells were rinsed, and the Alexa Fluor fluores-
cence of 10,000 cells was measured in a flow cytometer.
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Biological studies
MCA207 cells were maintained in DMEM media
supplemented with 10% heat-inactivated FCS, 2 mM
L-glutamine, 100 U/mL penicillin, and 100 mg/mL
streptomycin, under 5% CO2. Flow cytometric analysis
of the cells was performed as we have described previ-
ously, using the Flow Cytometry Core facility of
the University of Michigan.52 For the in vitro 2-photon
optical fiber fluorescence studies, cells plated in 75-mL
flasks were trypsinized, rinsed, and resuspended in PBS
containing 0.1% bovine serum albumin. For the in
vitro analyses, the cells in suspension were treated with
different concentrations of the conjugates for 1 hour at
37C, rinsed, and centrifuged to collect the cell pellets.
The double-clad fiber was then inserted into different
regions of the cell pellet, and the 2-photon optical fiber
fluorescence counts were collected as previously
described.53
For the in vivo studies, MCA207-control or
MCA207-HER2 cell tumors were developed in 7-week-
old SCID mice as described before.52 The mice were
housed in a specific pathogen-free animal facility at the
University of Michigan Medical Center in accordance
with the regulations of the University’s Committee on
the Use and Care of Animals as well as with federal
guidelines, including the Principles of Laboratory Ani-
mal Care. The animals were fed ad libitum with Labora-
tory Autoclavable Rodent Diet 5010 (PMI Nutrition
International, St Louis, Mo). The cells were trypsinized,
rinsed, and injected as a 0.1-mL suspension using sterile
PBS. The tumors were allowed to reach 0.7 to 0.8 cm in
diameter before analysis. Two nanomoles (1.3 lM ini-
tial circulating concentration for 1.5 mL of mouse blood
volume) of the conjugates in 0.1 mL of PBS or PBS
alone as a control were administered through the tail
vein. Fifteen hours later, the mice were euthanized with
isoflurane, and the tumors were immediately excised and
frozen. The 15-hour time point was selected based on
our previous observation that a trastuzumab-FITC con-
jugate saturates the MCA207-HER2 tumor between 4
and 24 hours.52 The optical fibers were inserted into the
tumor through a 30-gauge needle, with the tip of the
fiber placed at the proximal end of the needle hole. The
needle with the fiber was sonicated in a bath sonicator
between tumor sample measurements. The fluorescence
of multiple internal regions of the tumors was recorded
for 60 seconds during insertions of the needle through 2
to 3 mm tumor depth, manually controlled by a 2-
dimensional translational stage.
The statistical significance of differences among the
groups was analyzed by the Student-Newman-Keuls test,
with significance calculated at P< .05.
RESULTS
We initially verified if the newly synthesized products
were biologically active by flow cytometry analyses using
purified conjugates. As demonstrated in Figure 1B, the
trastuzumab-Alexa Fluor 633 conjugate bound to the
MCA207-HER2 cells in a dose-dependent and saturable
fashion, whereas the MCA207-control cells failed to bind
to the conjugate, confirming the retention of its binding
activity. The binding onto the MCA207-HER2 cells was
completely blocked by a 10-fold excess of free trastuzu-
mab (data not shown), indicating the receptor specificity
of the conjugate.
Figure 2. Linearity of the 2-photon optical fiber fluorescence
(TPOFF) measurements of standard solutions of the dyes
Alexa Fluor 594 and Alexa Fluor 660 is shown. The double-
clad fiber was dipped into solutions of the 2 dyes in phos-
phate-buffered saline, pH 7.4, and the TPOFF counts were
taken for a period of 60 seconds. (A) The fluorescence decay
curves of 300-nM solutions of the 2 dyes are shown. (B)
Mean TPOFF counts per second obtained for different con-
centrations of the 2 dyes are shown, corrected for buffer
background.
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We selected the 2 dyes, Alexa Fluor 594 and Alexa
Fluor 660, which are widely separated on their emission
spectra, for further in vitro and in vivo 2-photon optical
fiber fluorescence studies. Initially we verified the linearity
of the 2-photon optical fiber fluorescence counts, and as
given in Figure 2, the mean 2-photon optical fiber fluores-
cence counts of the 2 dyes were linear up to 1000 nM.
Conjugates of trastuzumab with these dyes were then used
to examine the utility of the 2-photon optical fiber fluo-
rescence to simultaneously measure the fluorescence in so-
lution by comparing their 2-photon optical fiber
fluorescence measured individually and as a mixture. For
this, the fluorescence emitted by the 2 conjugates was
measured using appropriate filters that selectively collect
the individual fluorescence of the 2 dye molecules in the
mixture. A mixture of 15 nM each of the 2 conjugates
gave half of the 2-photon optical fiber fluorescence counts
given individual conjugates measured separately at 30 nM
each (Fig. 3), demonstrating the quantitative nature of the
fluorescence measured in the mixture by 2-photon optical
fiber fluorescence. The double-clad fiber probe was then
used to quantify the targeted fluorescence of the 2 conju-
gates in cell pellets obtained from the cell lines. The con-
jugates bound to the MCA207-HER2 cells in a dose-
dependent and saturable fashion, whereas they completely
failed to bind to the MCA 207-control cells, which lack
the HER 2 receptor (Fig. 4), confirming the preliminary
flow cytometric data (Fig. 1B).
To gather proof of concept for the simultaneous tar-
geting of 2 different conjugates as a strategy for receptor
quantification, we administered the 2 Alexa Fluor-labeled
conjugates into mice bearing HER2-postive and HER2-
negative tumors. The conjugates were intravenously
injected into mice either individually or as their mixture
(2 nmol each, and in the mixture a total of 4 nmol com-
bined), and the fluorescence accumulated in the tumor
after a 15-hour time point was quantified by 2-photon op-
tical fiber fluorescence measurement. In support of the in
vitro targeting (Fig. 4) and our previous tumor targeting
of trastuzumab-FITC,52 both trastuzumab-Alexa Fluor
conjugates were specifically targeted into the MCA207-
HER2 tumors, whereas they failed to bind to MCA207-
control tumors (Fig. 5).
The tumor fluorescence of each conjugate was quan-
tified using appropriate filters that collected the specific
fluorescence emission of the conjugate administered (Fig.
5A and B). When the 2 conjugates were injected into the
mice as a mixture, both could be quantified simultane-
ously (Fig. 5C), similar to the demonstrated quantifica-
tion of the 2 mixtures initially verified in solutions (Fig.
3). Importantly, we observed that the 2 conjugates com-
peted for the receptor, thereby giving only half the
Figure 3. Simultaneous 2-photon optical fiber fluorescence
(TPOFF) measurement of the mixture of the 2 trastuzumab
conjugates (Herceptin [HN])-Alexa Fluor 594 and HN-Alexa
Fluor 660 is shown. The TPOFF of the 2 conjugates prepared
in phosphate-buffered saline (PBS) buffer was measured ei-
ther individually (30 nM each), or as a mixture of the 2 (15 nM
each), using a single excitation laser beam, and acquiring the
TPOFF counts using 2 different filters, 525  125 nm (solid
bars) and 680  15 nm (open bars), selected for capturing
the specific fluorescence of HN-Alexa Fluor 594 and HN-
Alexa Fluor 660, respectively.
Figure 4. In vitro targeting of trastuzumab (Herceptin [HN])
conjugates HN-Alexa Fluor (AF) 594 (triangle symbols) and
HN-AF 660 (square symbols) in human epidermal growth re-
ceptor 2 (HER2)-negative (open symbols) and HER2-positive
(filled symbols) MCA 207cells was determined by 2-photon
optical fiber fluorescence measurements. A suspension of 5 
106 cells in phosphate-buffered saline containing 0.1% bovine
serum albumin was incubated with different concentrations
of the conjugate for 1 hour at 37C, the cells were rinsed and
centrifuged, and the 2-photon optical fiber fluorescence
counts were taken in different regions of the cell pellet. The
data are given as the nanomolar concentration in the cell pel-
let, calculated from the 2-photon optical fiber fluorescence
counts obtained for the standard conjugate solutions.
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accumulated fluorescence in the tumor when given as
mixture versus when given to them individually, confirm-
ing the HER2-specific binding of the conjugate in the
tumor.
Knowing the 2-photon optical fiber fluorescence of
the standards of the trastuzumab-Alexa Fluor, the average
tumor fluorescence obtained can be converted to the aver-
age concentration of the conjugates in the tumor. As
shown in Figure 5C, the 2 conjugates when administered
individually showed an average concentration of about 60
nM, which is similar to the saturated levels obtained in
the in vitro uptake measured in the cell pellets (Fig. 4).
This suggests that at the 2-nmol doses of the conjugates
injected into the mice, the entire tumor HER2 was fully
occupied by each of the 2 conjugates. This is further sup-
ported by the observation that at a total of 4 nmol com-
bined administration of the 2 conjugates, there is nearly
half of the total fluorescence of that injected individually.
As trastuzumab is known to bind to HER2 at a 1:1 ratio,54
the concentration of trastuzumab bound at the saturating
concentration is equivalent to the concentration of the
average number of HER2 receptors present in the tumor.
As the data given in Figure 5 are derived from the mea-
surement of 4 to 5 separate regions of the tumor interior
while the needle was moved vertically over a span of 2 to 3
mm during each measurement, the average fluorescence
shown is representative of several thousand cells. There-
fore, the concentration of the HER2 derived from Figure
5C is a fair representation of the average HER2 in the
whole tumor mass.
DISCUSSION
Our study predicts the utility of the 2-photon optical fiber
fluorescence fiber probe as a tool to quantify the total
amount of overexpressed receptors such as HER2 or
EGFR in solid tumors. In addition, this study shows that
the intravenous administration of a mixture of
Figure 5. Simultaneous 2-photon optical fiber fluorescence
(TPOFF) measurement of the in vivo targeting of 2 trastuzu-
mab (Herceptin [HN]) conjugates HN-Alexa Fluor (AF) 594
and HN-AF 660 in mice xenograft tumors expressing human
epidermal growth receptor 2 (HER2) is shown. MCA207-con-
trol tumor and MCA207-HER2 tumors were developed in
SCID mice, respectively on the left and right flank areas of
each mouse. When the tumors reached an average of 0.8 cm
in diameter, 2 nmol each of the 2 conjugates was injected
through the tail vein, either individually, or as their mixture
(total 4 nmol of the 2 conjugates in the mixture). The control
mice were injected with the vehicle phosphate-buffered sa-
line (PBS). The tumors were isolated after 15 hours, and the
TPOFF counts were determined by inserting the fiber into
different regions of the tumor through a 30-gauge needle,
using 2 different filters as described in the legend for Figure
3. The open bars represent counts obtained for the MCA207-
control tumors, and the solid bars represent the counts
obtained for MCA-HER2 tumors. The data given are the mean
 standard error obtained for 4 to 5 different internal regions
of the tumor, each reading having been taken over a period
of 60 seconds while the needle was being slowly moved
inwardly. (A) Mean TPOFF counts were obtained using the
525  125 nm filter. (B) Mean TPOFF counts were obtained
using the 660  15 nm filter. (C) The nanomolar concentra-
tions of the 2 conjugates in the tumor were calculated from
the TPOFF counts obtained for the standard conjugate
solutions.
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fluorescently tagged antibodies would allow the simulta-
neous quantification of 2 or more receptors. The currently
practiced immunohistochemical and FISH methods for
quantification of the HER2 rely on in vitro analyses of tis-
sues removed during surgery or by needle biopsy. The lat-
ter method often requires repeated insertion of larger-
gauge needles to retrieve sufficient tissue sample needed
for analyses. As the 2-photon optical fiber fluorescence
probe can be inserted into the tumor using an ultrafine
30-gauge needle, this method can serve as an alternative,
minimally invasive method to quantify the receptors by
using appropriate fluorescent ligands administered intra-
venously. The 2-photon optical fiber fluorescence method
also has the potential advantage that it quantifies the
native HER2 in live cells without introducing experimen-
tal artifacts because of tissue processing and storage, limi-
tations inherent in the conventional methods. The
biologically relevant HER2 is only that which is expressed
on the cell surface and not that seen in the cell interior. As
the systemically administered HER2 antibody accumu-
lates in the tumor via extracellular binding after delivery
from the circulation, the fluorescence measured will be
proportional to the cell surface-expressed HER2.
Although in the current study the 2-photon optical fiber
fluorescence measurements were made in isolated tumors,
based on our previous findings on the feasibility of tumor
fluorescence quantification in live animals,52 we believe
these studies can be extended to receptor quantification in
live animal tumors.
The application of the 2-photon optical fiber fluo-
rescence method for receptor quantification relies on the
tumor-specific binding of the ligands (eg, trastuzumab)
onto the receptor, which may be dependent on the ligand
pharmacokinetics, clearance from the normal tissues, tu-
mor penetration, and tumor size. Although the variability
of pharmacokinetics and tumor availability may compro-
mise the usefulness of this method to correctly translate
the observed fluorescence to tumor receptor levels, further
validation of this technique by determining the kinetics of
the ratio of the fluorescence of tumor versus blood and tu-
mor versus adjacent tissue (eg, normal breast tissue, the
fluorescence of which can be simultaneously recorded
during insertion of the needle into the breast) may estab-
lish its clinical utility. In support to this view, several
recent studies in animal tumor models have shown high
specific uptake of radiolabeled HER2 antibody in the tu-
mor, with tumor to tissue/blood ratio reaching a maxi-
mum from 48 to 72 hours,55 and HER2-positron
emission tomography scanning is currently being eval-
uated as a possible imaging tool for HER2-positive breast
tumor.56 One drawback of the trastuzumab antibody
used in this study is its observed cardiotoxicity.25 None-
theless, any observed toxicity problems can be solved by
choosing ligands that bind to the receptor without activat-
ing any cellular signal transduction pathways. One such
possibility is the design of a fluorescently labeled den-
drimer nanoparticle carrying polyvalent small molecule
peptides or scFv-Fc fragments that bind to the HER2
without mediating any cellular signal activation path-
ways.53 For clinical application, it is also crucial that the
toxicity of the conjugated dye is thoroughly examined.
Multiple insertions of the needle through different areas
within the tumor are needed for the accurate quantifica-
tion of average receptor number in the whole tumor vol-
ume. However, if the tumor position within the breast
tissue is correctly identified by magnetic resonance imag-
ing or computed tomography scan, it is possible that the
needle can be inserted into multiple internal tumor
regions without having to pull out the needle completely
from the breast or even the tumor by choosing different
angles to direct the needle from the same insertion point
on the tumor surface during a single breast insertion.
In conclusion, our study shows the applicability of a
novel optical fiber method to quantify overexpressed
receptors in a tumor simultaneously by a few insertions of
the 2-photon optical fiber fluorescence probe using an
ultra-fine 30-gauge needle.
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